Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway
- 1 May 2012
- journal article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 83 (9), 1251-1260
- https://doi.org/10.1016/j.bcp.2012.01.023
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (90913020)
- Joint Fund of National Natural Science Foundation of China-Guangdong Province (U0932004)
- Fundamental Research Funds for the Central Universities (21611314, 21611407, 21611405)
This publication has 53 references indexed in Scilit:
- ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic DiseaseEuropean Urology, 2011
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumorsJournal of Surgical Oncology, 2011
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2006
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJournal of Clinical Oncology, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerThe New England Journal of Medicine, 2004
- VEGF and the quest for tumour angiogenesis factorsNature Reviews Cancer, 2002
- Mechanisms of normal and tumor-derived angiogenesisAmerican Journal of Physiology-Cell Physiology, 2002
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971